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ABSTRACT
Advanced non-small cell lung cancer (NSCLC) is a complex
disease comprising molecularly distinct tumor types, each with a
unique biology that is becoming increasingly better character-
ized. The aim of this review is to present an optimized treatment
schema and the accompanying diagnostic testing approach for
patients with advanced NSCLC. There are a number of therapies
currently approved for patients with advanced NSCLC, including
agents that target particular oncogenic drivers, as well as
immune checkpoint blockers (ICBs) that elicit an antitumor
response. Identiﬁcation of genetic alterations (e.g., epidermal
growth factor receptor, anaplastic lymphoma kinase, reactive
oxygen species proto-oncogene 1, B-Raf proto-oncogene) or pro-
grammed cell death ligand-1 expression levels in NSCLC requires
diligent molecular testing at initial diagnosis and, in some cases,
at disease progression to ensure the most efﬁcacious treatment
is delivered. Accurate molecular diagnostic testing, along with
the careful selection of currently approved targeted agents, ICBs,
or systemic chemotherapy, provides therapy that is personalized
according to patients’ needs to achieve the best possible out-
come. Enrollment in clinical trials that further the development
of tailored therapies is highly recommended at all stages of treat-
ment. TheOncologist 2019;24:1–15
Implications for Practice: Targeted therapies and immune checkpoint blockers provide effective and tailored options for
patients with non-small cell lung cancer. Careful molecular analysis of tumor samples is necessary to identify the genetic
alterations that are present, to ensure that each patient receives the most efﬁcacious treatment for their speciﬁc tumor
type. Personalized therapy provides each patient with the best probability for prolonged survival. Enrolling patients in clini-
cal trials should be the ﬁrst consideration before making each treatment decision.
INTRODUCTION
Non-small cell lung cancer (NSCLC) comprises 84% of all lung
cancers [1]. Histologically, NSCLC is classiﬁed into two subtypes:
nonsquamous cell carcinoma and squamous cell carcinoma
(SCC). Within the nonsquamous category, adenocarcinoma is
the predominant type, followed by large cell (undifferentiated)
carcinoma and other rare cell types. Histologic classiﬁcation of
NSCLC is important for selection of therapy. In addition to histo-
logic analysis, molecular characterization of tumors may iden-
tify genetic alterations for which targeted therapies or immune
checkpoint blockers (ICBs) are available (Table 1). Identifying
the genetic alterations that are present ensures that patients
with NSCLC receive the most efﬁcacious treatment for their
speciﬁc tumor type.
The frequency of molecular alterations in NSCLC varies
with tumor histology. In patients with lung adenocarcinoma,
60% of tumors contain a driver alteration [2]. Mutations in
the epidermal growth factor receptor gene (EGFR) are found
in 19% of patients with adenocarcinoma and in 3% of
patients with squamous histology [3]. Rearrangements in the
anaplastic lymphoma kinase gene (ALK) and the reactive oxy-
gen species proto-oncogene 1 (ROS1) occur in 5% and 1% of
NSCLC cases, respectively [4, 5]. Alterations in EGFR, ALK,
ROS1, and the B-Raf proto-oncogene (BRAF) are not typically
found in the same tumor, and each driver represents a distinct
molecular subgroup of NSCLC with unique targeted therapy
options. Targeted therapies for other rare genetic alterations
are under investigation in the erb-b2 receptor tyrosine kinase
2 gene (ERBB2), the mesenchymal-epithelial transition gene (a
prototypical receptor tyrosine kinase gene; MET), and the ret
proto-oncogene (a receptor tyrosine kinase gene; RET), each of
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Table 1. Summary of data on efﬁcacy and safety of targeted agents in metastatic NSCLC
Agent Line Approved for use
FDA-approved
diagnostic testa Pivotal trial n
Median PFS
(95% CI), mo [HR; p]
Median OS
(95% CI), mo
AEs ≥20% (Grade 1–2)/
all AEs Grade ≥3d
FDA-approved
EGFR mutation
Erlotinib 1 Patients with
metastatic NSCLC
whose tumors
have EGFR exon
19 deletions or
exon 21 (L858R)
substitution
mutations, as
detected by an
FDA-approved test
[85]
cobas EGFR
Mutation Test v2,
Roche Molecular
Systems, Inc.
cobas EGFR
Mutation Test,
Roche Molecular
Systems, Inc.
EURTAC [13] 86 9.7 (8.4–12.3) 19.3 (14.7–26.8) Grade 1–2: rash (67%), diarrhea
(52%), fatigue (51%), appetite loss
(31%)
Grade ≥3: rash (13%), diarrhea
(5%), fatigue (6%)
Afatinib 1 Patients with
metastatic NSCLC
whose tumors
have EGFR exon
19 deletions or
exon 21 (L858R)
substitution
mutations, as
detected by an
FDA-approved test
[86]
therascreen EGFR
RGQ PCR Kit,
Qiagen Manchester
Ltd.
LUX-Lung 3 [14],
LUX-Lung 6 [87]
LUX-Lung 3: 229
LUX-Lung 6: 242
LUX-Lung 3: 11.1
LUX-Lung 6: 11.0
(9.7–13.7)
LUX-Lung 3: NR
LUX-Lung 6: 22.1
(20.0–NR)
LUX-Lung 3: Grade 1–2: rash/acne
(73%), diarrhea (81%), dry skin
(29%), stomatitis/mucositis (63%),
paronychia (45%)
Grade ≥3: rash/acne (16%),
diarrhea (14%),
stomatitis/mucositis (9%),
paronychia (11%)
LUX-Lung 6: Grade 1–2: rash/acne
(66%), diarrhea (83%),
stomatitis/mucositis (46%),
paronychia (33%)
Grade ≥3: rash/acne (15%),
diarrhea (5%), stomatitis/
mucositis (5%)
Geﬁtinib 1 Patients with
metastatic NSCLC
whose tumors
have EGFR exon
19 deletions or
exon 21 (L858R)
substitution
mutations, as
detected by an
FDA-approved test
[88]
cobas EGFR
Mutation Test v2,
Roche Molecular
Systems, Inc.
therascreen EGFR
RGQ PCR Kit,
Qiagen
Manchester Ltd.
IPASSb[12]
IFUM [89]
IPASS: 609
IFUM: 106
IPASS: 5.7
IFUM: 9.7
(8.5–11.0)
IPASS: 18.6
IFUM: NR
IPASS: Grade 1–2: rash/acne
(63%), diarrhea (43%), dry skin
(24%), anorexia (20%)
Grade ≥3: rash/acne (3.1%),
diarrhea (4%)
IFUM: Grade 1–2: rash (45%),
diarrhea (27%)
Grade ≥3: diarrhea (4%)
Osimertinib 1 Patients with
metastatic EGFR
T790M mutation-
positive NSCLC, as
detected by an
FDA-approved test
[51]
cobas EGFR
Mutation Test v2,
Roche Molecular
Systems, Inc.c
FLAURA [15] 556 PFS: 18.9
(15.2–21.4)
vs. erlotinib or
geﬁtinib: 10.2
(9.6–11.1) [HR,
0.46; 95% CI,
0.37–0.57;
p < .0001]
Interim analysis:
NR vs. erlotinib or
geﬁtinib: NR
Grade 1–2: rash/acne (57%),
diarrhea (56%), dry skin (35%),
paronychia (35%)
Grade ≥3: rash/acne (1%),
diarrhea (2%), dry skin (<1%),
paronychia (<1%)
Osimertinib 2 Patients with
metastatic EGFR
T790M mutation-
positive NSCLC, as
detected by an
FDA-approved test,
who have
progressed on or
after EGFR-TKI
therapy [51]
cobas EGFR
Mutation Test v2,
Roche Molecular
Systems, Inc.c
AURA2 [90]
AURA Extension
[91]
AURA3 [52]
AURA2: 199
AURA Extension: 198
AURA3: 279
AURA2 PFS via
BICR: 9.9
(8.5–12.3)
AURA Extension:
PFS: 12.3
(9.5–13.8)
AURA3: 10.1
(8.3–12.3) vs.
platinum-doublet
chemotherapy: 4.4
(4.2–5.6)
[HR, 0.30; 95% CI,
0.23–0.41;
p < .001]
AURA2 DoR via
BICR: 11.4 (9.0–NR)
AURA Extension:
NR
AURA3: NR
AURA2: Grade 1–2: rash (40%),
diarrhea (33%), paronychia (26%)
Grade ≥3: rash (1%), diarrhea
(<1%)
AURA Extension: Grade 1–2: rash
(39%), diarrhea (42%), paronychia
(31%), dry skin (31%)
Grade ≥3: rash (<1%), diarrhea
(<1%)
AURA3: Grade 1–2: rash (34%),
diarrhea (41%), paronychia (22%),
dry skin (23%)
Grade ≥3: rash (1%), diarrhea
(1%)
ALK rearrangement
Crizotinib 1 Patients with
metastatic NSCLC
whose tumors are
ALK positive, as
detected by an
FDA-approved test
[92]
VENTANA
ALK (D5F3)
CDx Assay, Ventana
Medical
Systems, Inc.
Vysis ALK
Break Apart FISH
Probe Kit, Abbott
Molecular, Inc.
PROFILE 1014 [21] 172 10.9 (8.3–13.9)
vs. chemotherapy
7.0 (6.8–8.2) [HR,
0.45; 95% CI,
0.35–0.60;
p < .001]
NR Grade 1–2: vision disorder (70%),
diarrhea (59%), edema (48%),
vomiting (44%), constipation
(41%), upper respiratory infection
(32%), abdominal pain (26%),
dysgeusia (26%), increased
transaminases (22%), headache
(21%)
Grade ≥3: vision disorder (1%),
diarrhea (2%), edema (1%),
vomiting (2%), constipation (2%),
dysgeusia (26%), increased
transaminases (14%),
headache (1%)
Ceritinib 1 Patients with
metastatic NSCLC
whose tumors are
ALK positive, as
detected by an
FDA-approved test
[23]
ASCEND-4 [22] 376 16.6 (12.6–27.2)
vs. chemotherapy
8.1 (5.8–11.1)
[HR, 0.55; 95% CI,
0.42–0.73;
p < .00001]
NR (29.3–NR)
vs. chemotherapy
26.2 (22.8–NR)
Grade 1–2: diarrhea (80%),
nausea (66%), vomiting (61%),
increased ALT (29%), increased
AST (36%), decreased appetite
(33%), increased blood alkaline
phosphatase (22%), fatigue (25%),
abdominal pain (23%), cough
(24%), decreased weight (20%),
increased blood creatinine (20%)
Grade ≥3: diarrhea (5%), nausea
(3%), vomiting (5%), increased
ALT (31%), increased AST (17%),
increased gamma-
glutamyltransferase (29%),
decreased appetite (1%),
increased blood alkaline
phosphatase (7%), fatigue (4%),
abdominal pain (2%), decreased
weight (4%), increased blood
creatinine (2%), upper abdominal
pain (2%), noncardiac chest pain
(1%), back pain (2%), asthenia
(3%), dyspnea (2%), anemia (2%),
neutropenia (1%)
(continued)
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Table 1. (continued)
Agent Line Approved for use
FDA-approved
diagnostic testa Pivotal trial n
Median PFS
(95% CI), mo [HR; p]
Median OS
(95% CI), mo
AEs ≥20% (Grade 1–2)/
all AEs Grade ≥3d
FDA-approved
Alectinib 1 Patients with
metastatic NSCLC
whose tumors are
ALK positive [56]
VENTANA ALK
(D5F3) CDx Assay
ALEX [24] 303 25.7 (19.9–NR)
vs. crizotinib 10.4
(7.7–14.6)
[HR, 0.47; 95% CI,
0.34–0.65;
p < .001]
Alectinib 2 Patients with
metastatic NSCLC
whose tumors are
ALK positive and
who have
progressed on or
are intolerant to
crizotinib [56]
Not associated
with an approved
test, but tumors
must have tested
positive for ALK to
have received ﬁrst-
line therapy
NP28761 [59]
(North American)
NP28673 (global)
NP28761: 69
NP28673: 138
ORR via IRC:
NP28761, 48%
(36–60)
NP28673, 50%
(41–59)
PFS: NP28761, 8.1
(6.2–12.6)
NP28673, 8.9
(5.6–11.3)
DoR via IRC:
NP28761, 13.5
(6.7–NE)
NP28673, 11.2
(9.6–NR)
NP28761: Grade 1–2: constipation
(33%), fatigue (25%), peripheral
edema (24%), myalgia (22%),
nausea (22%), diarrhea (21%),
headache (21%)
Grade ≥3: dyspnea (3%),
increased AST (2%), increased ALT
(2%), fatigue (1%), peripheral
edema (1%), myalgia (1%),
asthenia (1%), headache (1%),
vomiting (1%), diarrhea (1%)
NP28673: Grade 1–2: fatigue
(25%), constipation (33%),
myalgia (22%), peripheral edema
(24%)
Grade ≥3: fatigue (1%), myalgia
(1%), peripheral edema (1%)
Ceritinib 2 Patients with ALK-
positive metastatic
NSCLC who have
progressed on or
are intolerant to
crizotinib [23]
Not associated
with an approved
test, but tumors
must have tested
positive for ALK to
have received ﬁrst-
line therapy
ASCEND-1 [58] 163 PFS: 6.9 (5.6–8.7);
ORR via IA: 56%
(49–64%)
DoR 8.3 (6.8–8.7) Grade 1–2: diarrhea (80%),
nausea (77%), vomiting (57%),
abdominal pain (37%), fatigue
(38%), decreased appetite (36%),
constipation (30%), cough (29%),
abdominal pain upper (23%),
dyspnea (21%), back pain (20%),
increased aspartate
aminotransferase (23%)
Grade ≥3: diarrhea (6%), nausea
(6%), vomiting (4%), abdominal
pain (1%), fatigue (5%), decreased
appetite (2%), dyspnea (4%), back
pain (<1%), increased aspartate
aminotransferase (10%)
Brigatinib 2 Patients with ALK-
positive metastatic
NSCLC who have
progressed on or
are intolerant to
crizotinib [93]
Not associated
with an approved
test, but tumors
must have tested
positive for ALK to
have received ﬁrst-
line therapy
ALTA [61] 90 mg qd: 109
90 mg then
180 mg qd: 110
90 mg qd: 9.2
(7.4–15.6)
90 mg–>180 mg qd:
12.9 (11.1–NR)
Probability of OS at
1 year: 90 mg qd:
71%
90 mg–>180 mg
qd: 80%
90 mg qd: Grade 1–2: nausea
(32%), diarrhea (19%), vomiting
(22%), fatigue (27%), dyspnea
(24%), headache (28%), decreased
appetite (21%)
Grade ≥3: nausea (<1%), vomiting
(2%), constipation (<1%), fatigue
(2%), dyspnea (3%),
ILD/pneumonitis (2%), peripheral
neuropathy (<1%), rash (2%),
hypertension (6%), back pain
(2%), arthralgia (<1%), decreased
appetite (<1%), pneumonia (3%)
90 mg–>180 mg qd: Grade 1–2:
nausea (39%), diarrhea (38%),
vomiting (23%), fatigue (36%),
cough (34%), headache (26%),
rash (24%) Grade ≥3: nausea
(<1%), pyrexia (<1%), dyspnea
(2%), ILD/pneumonitis (3%),
hypoxia (3%), headache (<1%),
peripheral neuropathy (2%),
rash (4%), hypertension (6.4%),
back pain (2%), myalgia (<1%),
pain in extremity (<1%),
decreased appetite (<1%),
pneumonia (6%)
Lorlatinib 2 Patients ALK-
positive metastatic
NSCLC who have
progressed on
crizotinib and ≥1
other ALK inhibitor,
or alectinib or
ceritinib as the ﬁrst
ALK inhibitor
therapy [63]
Not associated
with an approved
test, but tumors
must have tested
positive for ALK to
have received ﬁrst-
line therapy
Study B7461001 215 ALK+ ORR, overall: 48%
(95% CI, 42–55);
previous crizotinib
and ≥1 ALK
inhibitor: 39%
(95% CI, 30–48);
previous alectinib
only: 31% (95% CI,
9–61); previous
ceritinib only: 46%
(95% CI, 19–75)
mDOR, overall:
12.5 months (95%
CI, 8.4–23.7)
Grade 1–2: mood effects (21%),
peripheral neuropathy (44%),
cognitive effects (25%), dyspnea
(22%), diarrhea (21%), arthralgia
(22%), edema (54%), fatigue
(26%), weight gain (20%)
Grade 3: mood effects (2%),
peripheral neuropathy (3%),
cognitive effects (2%), dyspnea
(5%), diarrhea (1%), arthralgia
(1%), edema (3%), fatigue (<1%),
weight gain (4%)
ROS1 rearrangement
Crizotinib 1 Patients with
metastatic NSCLC
whose tumors are
ROS1-positive [92]
Not associated
with an approved
test
PROFILE 1001 50 19.3 (95% CI,
14.8–NR)
Probability of
survival at
12 months: 79%
(95% CI, 65–88)
Grade 1–2: vision disorders (85%),
nausea (49%), edema (45%),
diarrhea (42%), vomiting (38%)
Grade 3: hypophosphatemia
(13%), neutropenia (9%),
increased transaminases (4%)
[no grade 4 TRAE]
BRAF V600E4
Dabrafenib +
trametinib
1 Patients with
metastatic NSCLC
whose tumors are
BRAF V600E4-
positive [31]
Oncomine Dx
Target Test,
Thermo Fisher
Scientiﬁc
Study BRF113928
(NCT01336634)
93 ORR via IRC:
n = 36; 61%
(95% CI, 44–77)
Responders with
DoR ≥6 months:
n = 22, 59%
Grade 1–2: increased blood
alkaline phosphatase (64%),
hyperglycemia (62%), increased
AST (57%), pyrexia (50%), fatigue
(46%), nausea (45%), leukopenia
(40%), hyponatremia (40%),
anemia (36%), neutropenia (36%),
vomiting (30%), diarrhea (30%),
dry skin (30%), decreased
appetite (29%),
hypophosphatemia (29%), edema
(28%), lymphopenia (28%),
increased ALT (26%), rash (25%),
chills (22%), cough (22%),
(continued)
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which is found in ≤3% of patients with lung adenocarcinoma
(Table 1) [6]. The most common mutation for which no tar-
geted therapy is available is a Kirsten ras oncogene homolog
gene (KRAS) mutation, which occurs in 25% of adenocarci-
noma [2, 7]. Although targeted agents are available for many
patients with adenocarcinoma, targeted therapies are very
rarely suitable for patients with SCC [7].
In addition to oncogenic driver mutations, tumor cell eva-
sion of the immune system can also lead to carcinogenesis.
Some tumor cells can exploit inhibitory immune checkpoints
regulated by programmed cell death-1 receptor (PD-1) and pro-
grammed cell death ligand-1 (PD-L1) through expression of PD-
L1 on the tumor cell to prevent T cell activation. An analysis of
three global clinical trials involving 4,784 patients with NSCLC
found that 66% of all tumors had measurable PD-L1 expression
[8]. When separated by histology, 74% of patients with non-
squamous histology and 81% of patients with squamous histol-
ogy had measurable PD-L1 expression [8]. The monoclonal
Table 1. (continued)
Agent Line Approved for use
FDA-approved
diagnostic testa Pivotal trial n
Median PFS
(95% CI), mo [HR; p]
Median OS
(95% CI), mo
AEs ≥20% (Grade 1–2)/
all AEs Grade ≥3d
FDA-approved
increased creatinine (20%),
hemorrhage (20%)
Grade ≥3: hyponatremia (17%),
lymphopenia (14%), anemia
(10%), hyperglycemia (9%),
leukopenia (8%), neutropenia
(8%), hypophosphatemia (7%),
increased AST (4%), increased ALT
(6%), dyspnea (5%), pyrexia (5%),
fatigue (5%), vomiting (3%), rash
(3%), hemorrhage (3%), diarrhea
(2%), creatinine increased (1%),
chills (1%), dry skin (1%)
Preliminary data for targeted agents in development
MET ampliﬁcation or MET exon 14 skipping
Crizotinib Investigational
phase I [94]
—e NCT00585195 12 mDoR: 35 (16–112) Most common all grade: diarrhea
(50%), nausea (31%), vomiting
(31%), peripheral edema (25%),
visual impairment (25%)
RET rearrangements
Cabozantinib Investigational
phase II [95]
—e NCT01639508 25 28% (12–49) Grade ≥3: lipase elevation (15%),
increased alanine
aminotransferase (8%), increased
aspartate aminotransferase (8%),
decreased platelet count (8%),
hypophosphatemia (8%)
Vandetanib Investigational
phase II [96]
—e LURET trial
(UMIN000010095)
17 ORR: 53% (28–77);
PFS: 4.7 (2.8–8.5)
Grade ≥3: hypertension (58%),
diarrhea (11%), rash (16%), dry
skin (5%), QT prolongation (11%)
Lenvatinib Investigational
phase II [97]
—e NCT01877083 25 ORR: 16%; PFS: 7.3
(3.6–10.2)
Grade ≥3: hypertension (68%),
nausea (60%), decreased appetite
(52%), diarrhea (52%), proteinuria
(48%), vomiting (44%)
HER2
Ado-trastuzumab
emtansine
Investigational
phase II basket [98]
—e NCT02675829 18 ORR: 44% (22–69);
PFS: 4 (3.0–NR)
mDoR: 5 (3.0–NR) TRAE: Grade 1–2: infusion
reaction (28%), fatigue (33%),
thrombocytopenia (33%),
increased AST or ALT (39%)
Grade 3: anemia (6%)
Ado-trastuzumab
emtansine
2 Investigational
phase II [99]
—e NCT02289833 49 ORR: 20%
(5.7–43.7); PFS: 2.6
(1.4–2.8)
mDoR: 7.3
(2.9–8.3); OS: 12.2
(5.2–NR)
Grade ≥3: fatigue (4%), dyspnea
(4%), seizure (2%), infusion-
related reaction (2%),
thrombocytopenia (1%)
Afatinib 2 Investigational
phase II [100]
—e NICHE,
NCT02369484
13 PFS: 15.9
(12.0–48.0)
Study closed early Grade 1–2: diarrhea (92%), oral
mucositis (23%), abdominal pain
(23%), vomiting (23%), erythema
multiforme (31%), acneiform rash
(31%), dry skin (23%), paronychia
(38%), fatigue (31%)
Grade ≥3: oral mucositis (8%),
dyspnea (16%), epistaxis (8%),
pleural effusion (8%), increased
gamma-glutamyltransferase
(8%), dehydration (8%),
hyperkalemia (8%), hyponatremia
(8%), urinary tract obstruction
(8%), anemia (8%), febrile
neutropenia (8%)
Trastuzumab +
paclitaxel
2 Investigational
phase II [101]
—e NCT02226757 24 ORR: 46% mDoR: 8.4
(3.6–13.3); OS:
36 (32.4–39.6)
Grade 1–2: fatigue (38%), myalgia
(42%), dyspnea (29%), neuropathy
(21%), headache (25%),
constipation (21%), nausea (21%)
Grade ≥3: fatigue (4%),
neuropathy (4%), decreased
neutrophil count (4%),
pneumonitis (4%), urinary tract
infection (4%)
ahttp://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm.
bPatient population was not selected for EGFR-sensitizing mutations.
cSamples can be formalin-ﬁxed, parafﬁn-embedded tissue, or plasma ctDNA.
dGrade 1/2 events are listed if they occurred in ≥20%; all grade ≥3 are listed.
eNot associated with an approved test.
Abbreviations: AE, adverse event; ALK, anaplastic lymphoma kinase gene; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BICR, blinded independent review committee;
BRAF, B-Raf proto-oncogene; CI, conﬁdence interval; ctDNA, circulating tumor; DoR, duration of response; EGFR, epidermal growth factor receptor; FDA, U.S. Food and Drug Administration;
HER2, human epidermal growth factor receptor 2 gene; HR, hazard ratio; IA, investigator assessment; ILD, interstitial lung disease; IRC, independent review committee; IRR, independent radi-
ology review; MET, mesenchymal-epithelial transition gene; mDoR, median duration of response; NE, not estimable; NR, not reached; NSCLC, non-small cell lung cancer; ORR: objective
response rate; OS, overall survival; PCR, polymerase chain reaction; PFS, progression-free survival; qd, once a day; RET, ret proto-oncogene; ROS1, reactive oxygen species proto-oncogene 1;
TKI, tyrosine kinase inhibitor; TRAE, treatment-related adverse event.
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antibodies anti-PD-1, anti-PD-L1, and anti-cytotoxic T-lympho-
cyte-associated protein 4 (CTLA-4) are ICBs that act to resensi-
tize suppressed immune cells and have been a focus of drug
development. Recently, anti-PD-1 and anti-PD-L1 agents were
approved for patients with advanced NSCLC (Table 2) [9–11].
NSCLC TREATMENT PARADIGM
Targeted therapies and ICBs provide effective and tailored
options for patients with NSCLC. National Comprehensive Can-
cer Network (NCCN) Clinical Practice Guidelines in Oncology
(NCCN Guidelines) for Non-Small Cell Lung Cancer V.1.2019
recommend that all patients with metastatic adenocarcinoma
should have their tumor tissue tested for actionable driver
mutations [7]. Patients with squamous histology should be
tested if the patient has never been a smoker or has mixed his-
tologies or at the discretion of the treating physician. The order
of molecular testing and corresponding use of these agents are
very important in the treatment of NSCLC. For example, testing
for actionable targets (i.e., EGFR, ALK, ROS1, and BRAF V600E)
should be conducted ﬁrst, before PD-L1 expression, because
patients with positive tests for EGFR mutations and ALK rear-
rangements have high response rates to tyrosine kinase inhibi-
tors (TKIs) but low response rates to PD-L1 antibodies.
Here, we provide testing and treatment schemata (Figs. 1–3),
inclusive of recent U.S. Food and Drug Administration (FDA)
approvals, that summarize how to identify and treat different
populations of patients with NSCLC (Fig. 1, targeted thera-
pies; Fig. 2, immunotherapeutic agents; Fig. 3, therapies for
patients ineligible for targeted therapy or immunotherapy).
Note that some of these agents are not recommended by
NCCN for various reasons, including if the drugs have not yet
been FDA approved for NSCLC.
Nonsquamous Histology: First-line Targeted
Therapies
First-line, FDA-approved agents for patients with advanced or
metastatic NSCLC with mutations in EGFR (exon 19 deletions,
exon 21 L858R substitution, as detected by an FDA-approved
test) include the EGFR-TKIs geﬁtinib, erlotinib, afatinib, and osi-
mertinib (Table 1). Geﬁtinib, erlotinib, and afatinib are selec-
tive for EGFR-sensitizing mutations; osimertinib is selective for
both EGFR-sensitizing and EGFR T790M resistance mutations.
In the patient population that is EGFRmutation-positive, these
agents have a response rate of approximately 70%, have suc-
cessfully extended the median progression-free survival (PFS)
by about 1 year, and have a median overall survival (OS) of
approximately 19 months [12–15]. Osimertinib signiﬁcantly
improved PFS compared with geﬁtinib or erlotinib in FLAURA
[15]. Osimertinib is the agent of choice not only because of its
superior efﬁcacy but also because of its mild toxicity proﬁle
and ability to treat and delay brain metastases. Based on
results from the FLAURA trial, osimertinib is recommended by
NCCN as the preferred ﬁrst-line option in patients with locally
advanced or metastatic NSCLC who have sensitizing EGFR
mutation [7]. The EGFR-TKI dacomitinib signiﬁcantly improved
PFS [16] and OS [17] compared with geﬁtinib in ARCHER 1050.
Dacomitinib recently received FDA approval, but this is unlikely
to change current practice.
Combination therapies are being assessed. Geﬁtinib in com-
bination with carboplatin plus pemetrexed increased median
OS (52.2 vs. 38.8 months; p = .013) and PFS (20.9 vs.
11.2 months; p < .001), but not PFS2 (20.9 vs. 21.1 months;
p = .806), compared with geﬁtinib alone, in NEJ009 [18].
Addition of bevacizumab to erlotinib therapy increased median
PFS (16.0 vs. 9.7 months; p = .0015) [19], but not OS [20], in
JO25567. However, with osimertinib being the agent of choice,
studies must be conducted with osimertinib combinations ver-
sus single-agent osimertinib.
Patients with ALK rearrangement-positive NSCLC beneﬁt
from ALK TKIs (crizotinib, ceritinib, alectinib; Table 1) [21, 22].
Crizotinib is an ALK, ROS1, and MET inhibitor; ceritinib inhibits
ALK and IGF-R1; and alectinib inhibits ALK and RET. Crizotinib is
FDA approved for ﬁrst-line use in patients with ALK-rearranged,
locally advanced, or metastatic NSCLC based on the PROFILE
1014 trial that demonstrated signiﬁcantly longer median PFS
with crizotinib compared with chemotherapy (10.9 vs.
7.0 months; p < .001) [21]. Ceritinib was recently approved
in the ﬁrst line in ALK-rearranged NSCLC based on the phase
III ASCEND-4 trial [23]. Ceritinib-treated patients had signiﬁ-
cantly longer median PFS compared with the chemotherapy
group (16.6 vs. 8.1 months; p < .00001) [22]. Furthermore,
alectinib has recently been FDA approved and is recom-
mended by NCCN as the preferred ﬁrst-line option (category 1)
in patients with metastatic, ALK-rearranged NSCLC based on
the phase III ALEX study that found a signiﬁcantly longer
median PFS with alectinib compared with patients receiving
crizotinib (25.7 vs. 10.4 months; p < .001) and on its ability to
treat and delay brain metastases [24]. In a recent ﬁrst interim
analysis from ALTA-1L, brigatinib increased estimated 12-month
PFS compared with crizotinib (67% vs. 43%; p < .001) in patients
with ALK-rearranged NSCLC who had not previously received
ALK inhibitors [25, 26]. Frontline phase III trials of lorlatinib or
ensartinib versus crizotinib are ongoing.
For patients with ROS1-rearranged NSCLC, crizotinib is
FDA approved for ﬁrst-line use based on the PROFILE 1001
phase I study (Table 1) [27, 28]. Of the 53 patients with ROS1
rearrangements who were treated with crizotinib, the median
PFS was 19.3 months, and the probability of survival at 6 and
12 months was 91% and 79%, respectively [27]. In a recent
phase II study in 28 patients with NSCLC and ROS1 rearrange-
ments who were treated with ceritinib, the median PFS with
ceritinib was 9.3 months [29]. Crizotinib is recommended by
NCCN as the preferred ﬁrst-line option over ceritinib for
patients with ROS1-rearranged NSCLC, based on the trial data
and the FDA approval [7]. Therapy with entrectinib in ROS1-
rearranged NSCLC is being assessed [30].
The BRAF inhibitor dabrafenib in combination with trameti-
nib is FDA approved for ﬁrst-line use in patients with advanced
or metastatic NSCLC who are BRAF V600E-mutation positive
[31]. In the phase II BRF113928 study, the overall response rate
(ORR) was 61% in the ﬁrst-line cohort (n = 36) and 63% in
patients who had received at least one previous platinum regi-
men (n = 57) [31].
For driver mutations without corresponding approved tar-
geted therapies for metastatic NSCLC (e.g., MET, RET, and
human epidermal growth factor receptor 2 [HER2]), NCCN rec-
ommends (category 2A) using targeted agents approved in
other indications or a clinical trial for the corresponding agent,
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Table 2. Summary of data on efﬁcacy and safety of ICBs approved for use in metastatic NSCLC
Agent Line Approved for use
Diagnostic
test Pivotal trial n
Median PFS
(95% CI), mo
Median OS
(95% CI), mo
AEs ≥10% (Grade 1–2)/
Grade ≥3
PD-1
Pembrolizumab +
pemetrexed +
carboplatin
1 Patients with
metastatic
nonsquamous
NSCLC [9]
NA KEYNOTE-021
Cohort G1 [40]
123 13.0 (8.3–NR) vs.
carboplatin/pemetrexed
8.9 (4.4–10.3). [HR,
0.53; 95% CI, 0.31–0.91;
p = .010]
NR (NR–NR) Grade 1–2: fatigue (68%),
peripheral edema (22%),
nausea (66%), constipation
(51%), vomiting (37%),
diarrhea (35%), rash (40%),
pruritus (24%), alopecia
(20%), dyspnea (36%), cough
(24%), decreased appetite
(31%), headache (31%),
dizziness (24%), dysgeusia
(20%), insomnia (24%),
upper respiratory tract
infection (20%), arthralgia
(15%)
Grade ≥3: fatigue (3%),
nausea (2%), vomiting (2%),
diarrhea (2%), rash (2%),
dyspnea (3%)
Pembrolizumab +
carboplatin +
nab-paclitaxel
or paclitaxel
1 Patients with
metastatic squamous
NSCLC [9]
NA KEYNOTE-407 [72] 559 6.4 (6.2–8.3)
vs. carboplatin/(nab)
paclitaxel 4.8 (4.3–5.7).
[HR, 0.56; 95% CI,
0.45–0.70; p < .001]
15.9 (13.2–NR)
vs. carboplatin/(nab)
paclitaxel 11.3
(9.5–14.8). [HR, 0.64;
95% CI, 0.49–0.85;
p < .001]
Grade 1–2: anemia (38%),
alopecia (46%), neutropenia
(15%), nausea (35%),
thrombocytopenia (23.8%),
diarrhea (30%), decreased
appetite (22%), constipation
(22%), fatigue (20%),
asthenia (19%), arthralgia
(19%), peripheral neuropathy
(19%), vomiting (16%), cough
(13%), dyspnea (12%)
Grade ≥3: anemia (16%),
alopecia (0.4%), neutropenia
(23%), nausea (1%),
thrombocytopenia (7%),
diarrhea (4%), decreased
appetite (2%), constipation
(<1%), fatigue (3%), asthenia
(2%), arthralgia (1%),
peripheral neuropathy (1%),
vomiting (0.4%), cough
(<1%), dyspnea (1%)
Pembrolizumab 1 Patients with metastatic
NSCLC whose tumors
have high PD-L1
expression (TPS ≥50%)
as determined by an
FDA-approved test, with
no EGFR or ALK
genomic tumor
aberrations, and no
previous systemic
chemotherapy
treatment for
metastatic NSCLC [9]
PD-L1 IHC
22C3
pharmDx test
KEYNOTE-024 [34] 305 10.3 (6.7–NR)
vs. platinum
combination
6.0 (4.2–6.2) p < .001
NR (NR–NR) Grade 1–2: diarrhea (10%),
pyrexia (10%), fatigue (11%),
nausea (10%)
Grade ≥3: diarrhea (4%),
anemia, fatigue (1%),
vomiting, pneumonitis,
severe skin reaction (4%),
colitis (1%), hypophysitis
(<1%), nephritis (<1%),
pancreatitis (<1%), type
1 diabetes mellitus (<1%)
Pembrolizumab 2 Patients with metastatic
NSCLC whose tumors
express PD-L1 (TPS ≥1%)
as determined by an
FDA-approved test, with
disease progression on
or after platinum-
containing
chemotherapy.
Patients with EGFR or
ALK genomic tumor
aberrations should have
disease progression on
FDA-approved therapy
for these aberrations
before receiving
pembrolizumab [9]
PD-L1 IHC
22C3
pharmDx
test
KEYNOTE-010 [67] 2 mg/kg: 139.
10 mg/kg: 151
2 mg/kg: 3.9 (3.1–4.1)
10 mg/kg: 4.0 (2.7–4.3)
vs. docetaxel 4.0
(3.1–4.2)
2 mg/kg: 10.4
(9.4–11.9) [0.71 (95%
CI, 0.58–0.88; p =
.0008)]
10 mg/kg: 12.7
(10.0–17.3) [0.61
(0.49–0.75; p < .0001)]
vs. docetaxel 8.5
(7.5–9.8)
(2 mg/kg): Grade 1–2:
fatigue (13%), decreased
appetite (13%), nausea
(11%); Grade ≥3: fatigue
(1%), decreased appetite
(1%), nausea (<1%)
(10 mg/kg):Grade 1–2:
fatigue (14%), rash (13%)
decreased appetite (10%);
Grade ≥3: fatigue (2%), rash
(<1%), decreased appetite
(<1%)
Nivolumab 2 Patients with metastatic
NSCLC with progression
on or after platinum-
based chemotherapy.
Patients with EGFR or
ALK genomic tumor
aberrations should have
disease progression on
FDA-approved therapy
for these aberrations
before receiving
nivolumab [10]
PD-L1 IHC
28-8
pharmDx
SQ: CheckMate-017
[76]
NSQ: CheckMate-057
[65]
CheckMate-017:
135
CheckMate-057:
292
CheckMate-017: 3.5
(2.1–4.9)
CheckMate-057:2.3
(2.2–3.3)
CheckMate-017: 9.2
(7.3–13.3) vs. docetaxel
6.0 (8.1–10.7) [HR, 0.59;
95% CI, 0.44–0.79; p <
.001]
CheckMate-057: 12.2
(9.7–15.0)
CheckMate-017: grade 1–2:
fatigue (15%), asthenia
(10%), decreased appetite
(10%); Grade ≥3: fatigue
(1%), decreased appetite
(1%)
CheckMate-057: Grade 1–2:
fatigue (15%), nausea (11%),
asthenia (10%), decreased
appetite (10%); Grade ≥3:
fatigue (1%), nausea (1%),
asthenia (<1%)
PD-L1
Atezolizumab 2 Patients with metastatic
NSCLC who have
disease progression
during or following
platinum-containing
chemotherapy. Patients
with EGFR or ALK
genomic tumor
aberrations should have
disease progression on
FDA-approved therapy
for these aberrations
before receiving
atezolizumab [11]
VENTANA
PD-L1
(SP142)
Assay
OAK [69] 425 2.8 (2.6–3.0) 13.8 (11.8–15.7) Grade 1–2: fatigue (24%),
decreased appetite (23%),
cough (23%)
Grade ≥3: fatigue (3%)
Abbreviations: AE, adverse event; ALK, anaplastic lymphoma kinase gene; CI, conﬁdence interval; EGFR, epidermal growth factor receptor; FDA, U.S. Food and Drug Administration; HR, hazard
ratio; ICB, immune checkpoint blocker; IHC, immunohistochemistry; NA, not applicable; NR, not reached; NSCLC, non-small cell lung cancer; NSQ, nonsquamous; OS, overall survival; PD-1,
programmed cell death-1 receptor; PD-L1, programmed cell death ligand-1; PFS, progression-free survival; SQ, squamous; TPS, tumor proportion score.
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if available [7]. Early-phase clinical trials have shown promising
results with the RET inhibitors LOXO-292 and BLU-667 [32, 33].
Among 30 patients with RET-positive NSCLC treated with LOXO-
292 in a phase I/II study, the ORR was 77% [32]. BLU-667 dem-
onstrated antitumor activity in a phase I study in patients with
RET-altered solid tumors, including NSCLC [33]. The question
remains: what is the optimal time to administer targeted thera-
pies that have not yet been approved for use in NSCLC? Most
of the data support their use in the second line or beyond.
Nonsquamous Histology: First-Line ICBs
When no actionable alterations are detected, ICBs have a
role in the treatment of metastatic NSCLC (Table 2). Mono-
therapy with the PD-1 receptor inhibitor pembrolizumab
gained ﬁrst-line approval based on the phase III KEYNOTE-
024 study of patients with metastatic NSCLC and high PD-
L1 expression (≥50% tumor proportion score [TPS]), with
no EGFR or ALK alterations (n = 305; Table 2) [9, 34]. First-
line pembrolizumab signiﬁcantly extended median PFS
(10.3 vs. 6.0 months; p < .001) and OS (estimated 6-month
OS rate of 80.2% vs. 72.4%; p = .005) compared with
platinum-based chemotherapy [34]. Signiﬁcance was main-
tained within the nonsquamous subset (n = 249) [34]. Pem-
brolizumab lacks efﬁcacy in TKI-naive patients with EGFR
mutations [35]. Recent results from the KEYNOTE-042 trial
conﬁrm OS beneﬁts with pembrolizumab in patients with
PD-L1 expression levels ≥1% (hazard ratio [HR], 0.81; 95%
conﬁdence interval [CI], 0.71–0.93; p = .0018) [36]. This is
of particular interest in light of the CheckMate-026 results
that showed that patients with NSCLC and PD-L1 expres-
sion levels ≥5% who were treated with nivolumab mono-
therapy did not improve their PFS compared with those
treated with chemotherapy (4.2 vs. 5.9 months) [37]. How-
ever, the beneﬁt in KEYNOTE-042 was driven by the >50%
Figure 1. Therapies for patients with NSCLC eligible for targeted therapies. Boxes with the dashed lines contain those drugs which
are not yet U.S. Food and Drug Administration (FDA) approved. Please see the text for treatment options for other actionable
mutations. Note that some of these agents are not recommended by NCCN for various reasons, including if the drugs have not
yet been FDA approved for NSCLC.
Abbreviations: ALK, anaplastic lymphoma kinase; BRAF, B-Raf proto-oncogene; EGFR, epidermal growth factor receptor; NSCLC,
non-small cell lung cancer; ROS1, reactive oxygen species proto-oncogene 1.
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PD-L1 expression group. The role of tumor mutation bur-
den (TMB) as a predictive biomarker is being assessed as
part of the CheckMate 227 trial, with initial results showing
increased PFS with nivolumab plus ipilimumab versus
platinum-doublet chemotherapy in patients with 10 or more
mutations per megabase (mut/Mb) compared with those
with fewer than 10 mut/Mb [38]. More data are needed to
assess whether TMB is a viable biomarker for predicting bene-
ﬁciaries of therapy; currently, it is neither FDA approved nor
ready for clinical use.
Pembrolizumab was granted accelerated approval for use
in metastatic nonsquamous NSCLC in combination with peme-
trexed and carboplatin, independent of PD-L1 expression [39].
The approval is based on results from KEYNOTE-021 in which
123 patients received either carboplatin plus pemetrexed plus
pembrolizumab or carboplatin plus pemetrexed alone as a
ﬁrst-line regimen and showed that the addition of pembrolizu-
mab signiﬁcantly extended PFS (13.0 vs. 8.9 months; p = .010)
[40]. However, OS data are pending, and it remains unclear if
giving an ICB concurrently is superior to using a sequential
approach. Pembrolizumab in combination with pemetrexed
and platinum was recently granted FDA approval as ﬁrst-line
therapy, based on KEYNOTE-189 trial data, which showed PFS
and OS beneﬁts with pembrolizumab plus pemetrexed plus
carboplatin (or cisplatin) compared with pemetrexed plus car-
boplatin (or cisplatin) alone [41]. Many other ICBs are being
evaluated in phase III clinical trials in the ﬁrst-line setting as
monotherapy or dual therapy, or in combination with chemo-
therapy (Table 3). Atezolizumab in combination with carbopla-
tin plus paclitaxel plus bevacizumab signiﬁcantly increased PFS
compared with carboplatin plus paclitaxel plus bevacizumab
alone in IMpower150 (19.2 vs. 14.7 months; HR, 0.78; 95% CI,
0.64–0.96; p = .016) [42], and the combination was recently
granted priority FDA review.
Nonsquamous Histology: First-Line Chemotherapy
Chemotherapy is a ﬁrst-line intervention when no actionable
biomarkers are detected and when pembrolizumab is not
Figure 3. Therapies for patients with NSCLC ineligible for tar-
geted therapy or immunotherapy. Note that NCCN recommends
many regimens for metastatic nonsquamous or squamous
NSCLC; this is an incomplete list. Some of these agents are not
recommended by NCCN.
Abbreviation: NSCLC, non-small cell lung cancer.
Figure 2. Immunotherapeutic agents for patients with NSCLC ineligible for targeted therapy. Boxes with the dashed lines contain
those drugs which are not yet U.S. Food and Drug Administration (FDA) approved. Note that some of these agents are not recom-
mended by NCCN for various reasons, including if the drugs have not yet been FDA approved for NSCLC.
Abbreviations: NSCLC, non-small cell lung cancer; PD-L1, programmed cell death ligand-1.
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suitable for the patient [7]. Pemetrexed plus a platinum-
based chemotherapy is the most common regimen, but
other platinum doublets are available. This combination is
recommended based on a phase III study of patients with
advanced NSCLC, in which the subanalysis of 1,000 patients
with nonsquamous histology found a statistically signiﬁcant
improvement in OS in patients who received the cisplatin
plus pemetrexed combination versus cisplatin plus gemcita-
bine (11.8 vs. 10.4 months; HR, 0.81; p = .005) [43]. Peme-
trexed maintenance therapy is also used in this population
based on the PARAMOUNT study, which found a signiﬁcant
reduction in the risk of disease progression (HR, 0.62; p <
.0001), improved OS (HR, 0.78; p = .0195), and increased PFS,
4.1 months (95% CI, 3.2–4.6) versus 2.8 months (95% CI, 2.6–
3.1), compared with placebo [44, 45]. A combination of carbo-
platin, paclitaxel, and bevacizumab can be used in selected
patients with nonsquamous NSCLC based on signiﬁcant im-
provements in the median OS (12.3 vs. 10.3 months; HR, 0.79;
p = .003) and PFS (6.2 vs. 4.5 months; HR, 0.66; p < .001) com-
pared with chemotherapy alone [46]. Bevacizumab should be
considered for patients without hemoptysis, cavitary, or central
tumors; however, patients with treated brain metastases can
be included for treatment with bevacizumab.
Nonsquamous Histology: Second-Line Targeted
Therapies
Rebiopsy is recommended for patients who progress on a ﬁrst-
line targeted therapy, as it may indicate the mechanism of drug
resistance. Themost commonly acquired resistancemechanism
to ﬁrst- and second-line EGFR-TKIs is the EGFR T790M muta-
tion, which occurs in 60% of cases [47–50]. Only osimertinib
is approved for use in patients with metastatic EGFR T790M
mutation-positive NSCLC, as detected by an FDA-approved liq-
uid biopsy or tumor test, who have progressed on or after
EGFR-TKI therapy with erlotinib, afatinib, or geﬁnitib [51]. The
AURA3 phase III trial found osimertinib to improve PFS signiﬁ-
cantly (10.1 vs. 4.4 months; p < .001) versus a platinum-based
doublet chemotherapy [51, 52]. Osimertinib is also a category
1 recommendation for patients withmetastatic NSCLCwho have
EGFR T790M mutation and symptomatic brain metastases [7].
As third-line treatment in EGFR T790Mmutated NSCLC, PFS with
osimertinib was 10.20 months compared with 2.95 months
with docetaxel-bevacizumab in a recently completed phase III
trial [53].
With osimertinib moving to the first-line setting, many
mechanisms of resistance are emerging. If an action-
ablemutation is found, the appropriate inhibitormay
be tried, or, in the case of transformation to small cell
lung cancer, the patient should be treated with
etoposide plus platinum. Otherwise, combination
chemotherapy is the treatment of choice.
With osimertinib moving to the ﬁrst-line setting, many
mechanisms of resistance are emerging. If an actionable muta-
tion is found, the appropriate inhibitor may be tried, or, in the
case of transformation to small cell lung cancer, the patient
should be treated with etoposide plus platinum. Otherwise,
combination chemotherapy is the treatment of choice. In an
EGFR/ALK mutation subgroup analysis of IMPower150, OS was
not reached in patients treatedwith atezolizumab plus bevacizu-
mab plus chemotherapy, compared with an OS of 17.5 months
for those treated with bevacizumab plus chemotherapy [42].
Upon progression, disease ﬂare occurs in 9%–23% of patients
when the EGFR-TKI therapy is discontinued [54, 55]. Therefore,
continuation of EGFR-TKI therapy until immediately before
starting an appropriate second-line regimen is recommended.
The ALK inhibitors ceritinib, alectinib, and brigatinib are
three FDA-approved, second-line options for patients with ALK
rearrangements who have progressed and are crizotinib-
resistant [23, 56, 57]. The open-label ASCEND-1 trial showed
that ceritinib beneﬁts this population, with an ORR of 56%,
median duration of response (DoR) of 8.3 months, andmedian
PFS of 6.9 months [58]. Alectinib was tested in two phase II
studies in crizotinib-resistant patients with measurable ALK-
positive NSCLC [59, 60]. The NP28761 trial of 69 evaluable
patients treated with alectinib showed an ORR of 48%, an esti-
mated median PFS of 8.1 months, and a DoR of 13.5 months
[60]. The NP28673 trial of 122 patients demonstrated similar
efﬁcacy of alectinib, with an ORR of 50% and a median PFS of
8.9 months [59]. Brigatinib was approved based on the ALTA
trial, a global, phase II registration study of patients with ALK-
positive NSCLC who were previously treated with crizotinib
[57]. Patients who received brigatinib (180mg once a day with
7-day, 90 mg lead-in) had a median PFS of 12.9 months [61].
Lorlatinib was recently granted FDA approval for patients pre-
viously treated with at least one ALK TKI, based on results from
a global, multicohort phase II study [62, 63]. In 215 patients
who were ALK-positive and who had received at least one pre-
vious ALK TKI, the ORR was 48% and the intracranial response
rate in 89 patients with CNS lesions at baseline was 60% [63].
These targeted therapies are currently being evaluated in
phase III clinical trials for use in the ﬁrst- second-, and third-
line settings (Table 4). In addition to these TKIs, other agents
are in development. The National Clinical Trials Network
ALK Master Protocol aims to tailor treatment based on the
molecular mechanism of resistance. This basket trial will be
opening soon.
Therapy with lorlatinib in ROS1-rearranged NSCLC is
being assessed [64]. Emerging evidence suggests that cabo-
zantinib is effective in patients with ROS1-positive NSCLC
that has become resistant to crizotinib or ceritinib.
Nonsquamous Histology: Second-Line ICBs
With pembrolizumab moving to the ﬁrst-line treatment setting,
the role of ICBs in the second line has diminished; however,
many important questions need to be addressed regarding the
optimal placement of an ICB in the treatment life of a patient.
Nivolumab is indicated for second-line use, regardless of PD-L1
status [10, 65, 66]. Nivolumab was tested against docetaxel in
CheckMate-057, a phase III study that showed that nivolumab
improved OS compared with docetaxel in patients with non-
squamous NSCLC (12.2 vs. 9.4 months). Although all patients
derived clinical beneﬁt from nivolumab, when data were strati-
ﬁed by PD-L1 expression, the magnitude of clinical beneﬁt
increased with increasing PD-L1 expression [65]. A PD-L1 com-
plementary diagnostic biomarker test to measure PD-L1 expres-
sion is not required for prescribing nivolumab in patients with
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nonsquamous NSCLC; however, the results of the complemen-
tary PD-L1 test may aid clinicians in deciding if nivolumab is
appropriate for patients [7].
Pembrolizumab is FDA approved in the second-line setting
for patients with metastatic, nonsquamous NSCLC and PD-L1
expression (TPS ≥1%) as determined by an FDA-approved,
companion diagnostic test, with disease progression on or
after platinum-containing chemotherapy, based on the phase
II/III trial, KEYNOTE-010 [67]. In this trial, in which 70% of
patients had nonsquamous histology, pembrolizumab (2 mg/kg
group) signiﬁcantly improved OS over docetaxel (10.4 vs.
8.5 months; p = .0008) [67]. The presence of microsatellite
instability-high (MSI) tumors in NSCLC is rare and is not as
routinely tested for as EGFR, ALK, ROS, BRAF, or PD-L1
alterations; however, when the patient obtains full molecular
proﬁling and the results show presence of MSI, then pembro-
lizumab is indicated and is the correct choice of therapy.
The anti-PD-L1 antibody atezolizumab has gained FDA
approval for second-line use, regardless of PD-L1 status, based
on the phase III OAK and phase II POPLAR trials [68, 69].
Among the 74% of patients with nonsquamous NSCLC, atezoli-
zumab treatment (n = 313) was associated with longer median
OS (15.6 months; 95% CI, 13.3–17.6) versus docetaxel-treated
patients (n = 315; 11.2 months; 95% CI, 9.3–12.6); the OS ben-
eﬁt associated with atezolizumab was statistically signiﬁcant
(HR, 0.73; 95% CI, 0.60–0.89; p = .0015) [69, 70]. Among
Table 3. Ongoing or planned phase III clinical trials of immune checkpoint blockers in metastatic NSCLC
NCT no.
(trial acronym) Agents Line Proposed n Study design
Planned study
completion date
Atezolizumab
NCT02813785
(IMpower210)
Atezolizumab
vs. docetaxel
2 563 Randomized, open-label in
patients after failure with
pCX; OS is primary
objective
May 2019
Avelumab
NCT02395172
(JAVELIN Lung
200)
Avelumab
vs. docetaxel
2 792 Randomized, open-label in
patients after failure with
pCX; OS is primary
objective
January 2023
NCT02576574
(JAVELIN Lung
100)
Avelumab vs. platinum
doublet
1 1,095 Randomized, open-label;
PFS and OS are primary
objectives
April 2024
Nivolumab
NCT02066636
(CheckMate 153)
Nivolumab 2 1,380 Randomized, open-label,
phase IIIb/IV safety trial in
patients who have
progressed during or after
≥1 systemic regimen
January 2022
NCT02613507
(CheckMate 078)
Nivolumab
vs. docetaxel
2 500 Randomized, open-label in
patients after failure with
pCX; OS is primary
objective
January 2020
NCT02713867
(CheckMate 384)
Nivolumab 2+ 620 Dose optimization study;
PFS at 6 months is primary
objective
June 2022
Pembrolizumab
NCT02578680
(KEYNOTE-189)
pCX + pemetrexed 
pembrolizumab
1 570 Randomized, open-label in
patients with nonsquamous
disease
April 2019
Durvalumab
NCT02453282
(MYSTIC)
Durvalumab 
tremelimumab vs. SoC
pCX
1 1,118 Randomized, open-label in
patients with no ALK- or
EGFR-activating mutations;
PFS is primary objective
December 2019
NCT02542293
(NEPTUNE)
Durvalumab +
tremelimumab vs. SoC
pCX
1 960 Randomized, open-label in
patients with no ALK- or
EGFR-activating mutations;
OS is primary objective
March 2019
NCT02352948
(ARCTIC)
Durvalumab 
tremelimumab vs. SoC
3+ 597 Randomized, open-label in
patients with PD-L1-
positive tumors; OS is
primary objective
December 2018
Abbreviations: ALK, anaplastic lymphoma kinase gene; EGFR, epidermal growth factor receptor; NCT, National Clinical Trial; NSCLC, non-small cell lung
cancer; OS, overall survival; pCX, platinum-based chemotherapy; PD-1, programmed cell death-1 receptor; PD-L1, programmed cell death ligand-1; PFS,
progression-free survival; SoC, standard of care.
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patients with the highest PD-L1 expression (PD-L1 expression
on ≥50% tumor cells or ≥10% immune cells), OS was 59%
greater in patients treated with atezolizumab versus docetaxel
(p < .0001). Even in patients with no PD-L1 expression, atezoli-
zumab provided a signiﬁcant 25% improvement in OS versus
docetaxel (p = .0215) [69]. Therefore, atezolizumab is approved
regardless of PD-L1 expression levels, although a complemen-
tary PD-L1 test may provide useful information to guide treat-
ment decisions [7, 11].
Nonsquamous Histology: Chemotherapy Second-Line
Therapy
For patients who have received the pembrolizumab-carbopla-
tin-pemetrexed combination in the ﬁrst line, several options
are recommended for second-line therapy, including docetaxel
with or without the anti-VEGF antibody ramucirumab [7].
Nonsquamous Histology: Chemotherapy Third-Line
Therapy
There is no standard therapy beyond second line, but
single-agent chemotherapy is a reasonable approach.
SCC: First-Line Targeted Therapy and ICBs
Squamous histology requires different considerations for ther-
apy selection. NCCN Guidelines recommend that molecular
testing can be considered, including for EGFR and ALK genetic
alterations, in patients with SCC if (a) the patient has never
smoked, (b) small biopsy samples were used to assess histol-
ogy, or (c) mixed histology was reported [7, 71]. ROS1 and
BRAF testing can also be considered. Molecular proﬁling can
also be employed at the discretion of the treating physician.
If actionable driver mutations are identiﬁed, treatment with
the corresponding targeted therapy is appropriate [7].
In patients with SCC who have high PD-L1 expression
(≥50% TPS), pembrolizumab is recommended for ﬁrst-line
intervention based on the KEYNOTE-024 trial described
previously [34]. For the squamous subgroup (n = 56), there
was a clear beneﬁt of pembrolizumab to the risk of disease pro-
gression or death (HR, 0.35; 95% CI, 0.17–0.71) [34]. Pembroli-
zumab in combination with chemotherapy (carboplatin with
paclitaxel or nab-paclitaxel) increased the objective response
rate compared with chemotherapy alone (58.4% vs. 35.0%;
p = .0004) in a ﬁrst interim analysis from KEYNOTE-407 [72].
The median OS and PFS were also signiﬁcantly improved with
pembrolizumab plus chemotherapy combination over chemo-
therapy alone (OS, 15.9 vs. 11.3 months; p = .0008. PFS, 6.4
vs. 4.8 months; p < .0001) [72]. Pembrolizumab in combination
with carboplatin and either paclitaxel or nab-paclitaxel was
recently granted FDA approval as ﬁrst-line therapy in patients
with metastatic squamous NSCLC, based on KEYNOTE-407 trial
data. Recent primary analyses from IMpower131 showed sig-
niﬁcantly increased PFS with atezolizumab in combination with
carboplatin plus nab-paclitaxel compared with carboplatin
plus nab-paclitaxel alone (6.3 vs. 5.6 months; HR, 0.71; 95%
CI, 0.60–0.85; p = .0001) [73]. The OS data are immature.
SCC: First-Line Chemotherapy
In the absence of a genetic driver mutation or expression of PD-
L1, NCCN recommends several chemotherapy options, includ-
ing cisplatin plus carboplatin plus gemcitabine, or a taxane for
ﬁrst-line intervention [7]. SWOG S0819 reconﬁrmed that pacli-
taxel plus carboplatin remains a treatment option for unse-
lected patients [74]. In this trial, which evaluated paclitaxel plus
carboplatin with or without cetuximab, there was no beneﬁt to
the addition of cetuximab regardless of histology. In patients
with squamous histology, themedian OSwas 8.0months. Gem-
citabine plus cisplatin is also a popular regimen based on a sub-
group analysis of a noninferiority trial in which ﬁrst-line
cisplatin plus gemcitabine was compared with cisplatin plus
pemetrexed in patients with advanced NSCLC. For patients
Table 4. Ongoing or planned phase III clinical trials of targeted therapy in locally advanced or metastatic NSCLC
NCT no. (trial acronym) Agents Line Proposed n Study design Planned completion date
EGFR mutation
NCT02474355 (ASTRIS) Osimertinib 2 3,515 Real-world setting, interventional,
in patients with EGFR T790M+
disease, OS is primary objective
April 2019
ALK rearrangement
NCT02737501 (ALTA-1L) Brigatinib vs. crizotinib 1 270 Randomized, double-blinded in
patients with ALK mutations; PFS is
primary objective
April 2021
NCT03596866 Brigatinib vs. alectinib 2 246 Randomized, open-label in patients
with ALK mutations; PFS is primary
objective
September 2023
NCT03052608 Lorlatinib vs. crizotinib 1 280 Randomized, open-label in patients
with ALK mutations; PFS is primary
objective
February 2023
NCT02838420 Alectinib vs. crizotinib 1 187 Randomized, open-label in Asian
patients with ALK mutations; PFS is
primary objective
December 2019
NCT02767804 Ensartinib vs. crizotinib 1 402 Randomized, open-label in patients
with ALK mutations; PFS is primary
objective
April 2020
Abbreviations: ALK, anaplastic lymphoma kinase gene; EGFR, epidermal growth factor receptor; NCT, National Clinical Trial; NSCLC, non-small
cell lung cancer; OS, overall survival; PFS, progression-free survival.
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with SCC, the OS was signiﬁcantly improved with cisplatin
plus gemcitabine versus cisplatin plus pemetrexed (10.8
vs. 9.4 months; HR, 1.23; 95% CI, 1.00–1.51; p = .05) [43].
This trial led to the removal of treatment of patients with
squamous histology from the pemetrexed label. Combina-
tion carboplatin plus nab-paclitaxel is a reasonable option
for SCC, based on a phase III subset analysis of patients with
SCC that demonstrated a signiﬁcantly higher ORR of 41%
(95% CI, 34.7–47.4) with carboplatin plus nab-paclitaxel ver-
sus carboplatin plus/solvent-based paclitaxel (ORR, 24%; 95%
CI, 18.8–30.1) [75]. Both continuation maintenance with gem-
citabine and switch maintenance with docetaxel are category
2B recommendations in NCCN Guidelines for patients with
SCC; both approaches have shown signiﬁcant PFS beneﬁts,
although with no signiﬁcant changes in OS [7].
Necitumumab plus cisplatin plus gemcitabine was removed
from the NCCN Guidelines as a regimen for patients with meta-
static SCC based on a lack of safety or efﬁcacy beneﬁt when
compared with cisplatin plus gemcitabine and other available
agents [7].
SCC: Second-Line ICBs
Nivolumab ﬁrst received FDA approval for the second-line
treatment of patients with squamous NSCLC, with no EGFR
or ALK genomic tumor aberrations, based on CheckMate-
017 [76]. Nivolumab signiﬁcantly increased OS compared
with docetaxel (9.2 vs. 6.0 months; p < .001) [76]. PD-L1
expression was neither prognostic nor predictive of efﬁcacy
in this patient population.
Pembrolizumab gained FDA approval for the second-line
treatment of patients with metastatic NSCLC with squamous
histology and PD-L1 expression (≥1% TPS), based on the
phase II/III KEYNOTE-010 trial previously summarized [67].
In this trial, 21% of patients had squamous histology, and
the improvement in OS associated with pembrolizumab was
not statistically signiﬁcant (HR, 0.74; 95% CI, 0.50–1.09), in
part owing to the small population size involved.
Atezolizumab has FDA approval regardless of PD-L1 status
based on the phase III OAK trial and the phase II POPLAR trial
[11, 68, 69]. In the 26% of patients with squamous NSCLC in
the OAK study, atezolizumab signiﬁcantly increased OS versus
docetaxel (8.9 months [95% CI, 7.4–12.8] vs. 7.7 months [95%
CI, 6.3–8.9]; HR, 0.73 [95% CI, 0.54–0.98]; p = .0383) [69].
Given the positive data obtained when ICBs are com-
bined with chemotherapy, second-line ICB usage will lessen.
Use of docetaxel plus or minus ramucirumab or afatinib
should be entertained.
SCC: Second-Line Therapy in Patients Ineligible for
Targeted Therapy or Immunotherapy
Afatinib has FDA approval for the treatment of patients with
advanced squamous cell lung carcinoma whose disease pro-
gressed after treatment with platinum-based chemotherapy,
based on LUX-Lung 8 trial results [77]. Docetaxel alone or in
combination with ramucirumab is also an approved second-
line option.
SCC: Third-Line Therapy
Therapeutic interventions following progression on a second-
line treatment are at the discretion of the patient and doctor.
DIAGNOSTIC TESTING
A biomarker test may help to identify patients who would ben-
eﬁt most from targeted therapy, ICBs, or a combination of ther-
apies. Diagnostic tests require sufﬁcient tissue and appropriate
timing [78]. As the number of tailored therapies increases,
there will be an increased need for testing algorithms that
ensure all necessary molecular tests have been performed.
Molecular Testing
The joint recommendation issued by the College of American
Pathologists, International Association for the Study of Lung
Cancer, and Association for Molecular Pathology strongly rec-
ommends molecular testing for EGFR and ALK in patients
with advanced lung adenocarcinoma at initial diagnosis and
at progression in those with lower-stage disease. Additionally,
it is strongly recommended that physicians employ EGFR and
ALK testing for tumors with histologies other than adenocarci-
noma, if there are clinical features that suggest a higher prob-
ability of detecting an oncogenic driver [79]. The updated
guidelines emphasize the importance of testing not only for
EGFR and ALK but also for ROS1, BRAF, and other driver
mutations [79]. NCCN Guidelines also strongly endorse broad
molecular proﬁling [7]. Movement away from single testing
to multiplex testing is encouraged to gain a comprehensive
biological analysis of a patient’s tumor.
Circulating Tumor Testing
Although tumor biopsy is considered the gold standard for
molecular analysis, “liquid” biopsies obtained from periph-
eral blood or urine present an opportunity for a less inva-
sive method to be used [80]. There are a number of
clinically validated methods available for circulating tumor
(ctDNA) testing [80, 81]. Although ctDNA testing has great
promise, it does have limitations. The amount of ctDNA a
tumor sheds is variable and can affect assay sensitivity
[82]. The sensitivities of liquid-based assays are typically
lower than those of tissue-based tests, and therefore there
is a possibility of false negatives [83]. For example, a nega-
tive plasma test result for EGFR T790M warrants a rebiopsy
to avoid missing an important actionable mutation [7, 83].
PD-L1 Testing
It is recommended that patients with metastatic NSCLC be
tested for PD-L1 expression before ﬁrst-line treatment [7]. The
Dako PD-L1 IHC 22C3 pharmDX companion diagnostic for pem-
brolizumab is recommended for use in the ﬁrst-line setting to
identify patients with a TPS of ≥50% who are suitable for pem-
brolizumab monotherapy; however, institutions may use their
own PD-L1 immunohistochemistry (IHC) testing platforms. The
inherent variability in the use of different PD-L1 IHC testing plat-
forms has been recognized by both industry and academia and
has brought about the Blueprint PD-L1 IHC Assay Comparison
Project that evaluated these tests for clinical comparability [84].
This study found that the assays cannot be considered to be
interchangeable for the determination of PD-L1 status [84]. Of
the four assays tested, all but the Ventana SP142 assay had
comparable tumor cell staining, and immune cell staining was
more variable than tumor cell staining [84]. PD-L1 testing is an
imperfect biomarker because of its dynamic expression, which
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may be inﬂuenced by a variety of factors; thus, there is an ongo-
ing and intensive search for other predictive biomarkers, such
as TMB.
PD-L1 testing is an imperfect biomarker because of
its dynamic expression, which may be influenced by
a variety of factors; thus, there is an ongoing and
intensive search for other predictive biomarkers,
such as TMB.
CONCLUSION
Both targeted therapies and ICB agents have an important role
in the treatment of NSCLC. In order to personalize therapy
appropriately, careful molecular analysis of tumor samples is
necessary to provide each patient with the best probability for
prolonged survival. However, there is still much work to be
done, and enrolling patients in clinical trials should be consid-
ered when making each treatment decision.
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